Carboplatin-d4 is intended for use as an internal standard for the quantification of carboplatin by GC- or LC-MS. Carboplatin is a platinum-containing DNA-crosslinking agent.1 It induces the formation of DNA interstrand crosslinks and DNA-protein crosslinks when used at concentrations of 200 and 300 µM. It inhibits the proliferation of GLC-4 small cell lung carcinoma and A2780 and SKOV3 ovarian cancer cells (IC50s = 22.7, 0.5, and 10.2 µM, respectively).2,3 Carboplatin reduces tumor growth in an ADJ/PC6 murine plasmacytoma model (ED90 = 0.6 mg/kg, i.p.).4 Formulations containing carboplatin have been used in the treatment of ovarian cancer.
1.Micetich, K.C., Barnes, D., and Erickson, L.C.A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cellsCancer Res.45(9)4043-4047(1985) 2.Groen, H.J., Sleijfer, S., Meijer, C., et al.Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell linesBr. J. Cancer72(6)1406-1411(1995) 3.Al-Eisawi, Z., Beale, P., Chan, C., et al.Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour modelsJ. Ovarian Res.6(1)78(2013) 4.Kelland, L.R., Abel, G., McKeage, M.J., et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drugCancer Res.53(11)2581-2586(1993)